Potential of CRISPR/Cas13 System in Treatment and Diagnosis of COVID-19

Abstract

The novel coronavirus disease 2019 (COVID-19) belongs to coronaviridae families like sarbecovirus (SARS), and causes pyrexia, pertussis, and acute respiratory distress syndrome (ARDS) in major. Started from Wuhan, China, COVID-19 now forced the World Health Organization (WHO) call it a global pandemic. These dreadful figures elevate the need for rapid action for a rapid diagnostic tool, an efficacious therapy, or vaccine for such widespread disease. In this article, we reviewed all the latest research and trials including conventional antiviral medicines that have a narrow and finite effect on COVID-19. Recently, some advances were made by a nucleotide/nucleoside analogues (NUC) inhibitor (remdesivir), ivermectin (antiparasitic drug), and convalescent plasma; the later one has more recently been approved by the Food and Drug Administration (FDA). Additionally, a clinical-grade soluble human angiotensin-converting enzyme (ACE2), named hrsACE2, was able to inhibit the infection of human blood vessel organoids, as well as the human kidney organoids, by the virus. As of now, innovative therapeutics based on the CRISPR/Cas13d might overcome the challenge of COVID-19 either as a treatment option or precise and rapid diagnostic tool due to its rapid and precise nature. In this updated comprehensive rapid review, we tried to cover all recent findings in terms of genomics, diagnosis, prevention, and treatment.

Keywords

COVID-19 - CRISPR/Cas13 - diagnosis - hrsACE2 - vaccines - ivermectin

Publication History

Article published online:
25 February 2021

• References

• 1 1st known case of coronavirus traced back to November in China. Accessed January 14, 2021 at: https://www.livescience.com/first-case-coronavirus-found.html
• 2 Media briefing on COVID-19. Available at: https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19—11-march-2020
• 3 Worldometer. COVID-19 coronavirus pandemic. Accessed January 14, 2021 at: https://www.worldometers.info/coronavirus/
• 4 Coronavirus disease (COVID-19) weekly epidemiological update and weekly operational update. Accessed January 14, 2021 at: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports
• 5 Miller A, Reandelar MJ, Fasciglione K, Roumenova V, Li Y, Otazu GH. Correlation between universal BCG vaccination policy and reduced morbidity and mortality for COVID-19: an epidemiological study. medRxiv 2020; DOI: 10.1101/2020.03.24.20042937.
• 6 Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Di Napoli R. Features, evaluation and treatment coronavirus. In: StatPearls. Treasure island, FL: StatPearls Publishing; 2020
• 7 Zehender G, Lai A, Bergna A. et al. Genomic characterization and phylogenetic analysis of SARS-COV-2 in Italy. J Med Virol 2020; 92 (09) 1637-1640
• 8 Lu R, Zhao X, Li J. et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 2020; 395 (10224): 565-574
• 9 Xu XW, Wu XX, Jiang XG. et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. BMJ 2020; 368: m606
• 10 Zhou Y, Yang L, Han M. et al. Case report on early diagnosis of COVID-19. Disaster Med Public Health Prep 2020; 1-4
• 11 Roche's cobas SARS-CoV-2 Test to detect novel coronavirus receives FDA emergency use authorization and is available in markets accepting the CE mark. Accessed January 14, 2021 at: https://diagnostics.roche.com/ir/en/news-listing/2020/roche-receives-fda-emergency-use-authorization-for-cobas-sars-co.html
• 12 QIAGEN to launch rapid portable test that can analyze over 30 samples per hour for SARS-CoV-2 antigen. Available at: https://corporate.qiagen.com/newsroom/press-releases/2020/20200908_access_antigen
• 13 Bordi L, Nicastri E, Scorzolini L. et al; On Behalf Of Inmi Covid-Study Group And Collaborating Centers. Differential diagnosis of illness in patients under investigation for the novel coronavirus (SARS-CoV-2), Italy, February 2020. Euro Surveill 2020;25(08):
• 14 Chen X, Yin YH, Zhang MY. et al. Investigating the mechanism of ShuFeng JieDu capsule for the treatment of novel Coronavirus pneumonia (COVID-19) based on network pharmacology. International Journal of Medical Sciences 2020; 17 (16) 2511
• 15 Morse JS, Lalonde T, Xu S, Liu WR. Learning from the past: possible urgent prevention and treatment options for severe acute respiratory infections caused by 2019-nCoV. ChemBioChem 2020; 21 (05) 730-738
• 16 Lab experiments show anti-parasitic drug, ivermectin, eliminates SARS-CoV-2 in cells in 48 hours. Accessed January 14, 2021 at: https://www.monash.edu/discovery-institute/news-and-events/news/2020-articles/possible-coronavirus-drug-identified-by-monash-university-scientists
• 17 Johns Hopkins gets FDA approval to test blood plasma therapy to treat COVID-19 patients. Accessed January 14, 2021 at: https://hub.jhu.edu/2020/04/03/blood-plasma-sera-covid-19-fda-approval/.
• 18 Monteil V, Kwon H, Prado P. et al. Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2. Cell 2020; 181 (04) 905-913.e7
• 19 Devlin H. Lessons from SARS outbreak help in race for coronavirus vaccine. Accessed January 14, 2021 at: https://www.theguardian.com/science/2020/jan/24/lessons-from-sars-outbreak-help-in-race-for-coronavirus-vaccine
• 20 “IGAL's Coronavirus Vaccine Project. Accessed January 14, 2021 at: https://www.migal.org.il/en/coronavirus-vaccine-project
• 21 Israeli scientists begin animal testing of COVID-19 vaccine prototype. Accessed January 14, 2021 at: https://www.pharmaceutical-technology.com/news/israel-covid-19-vaccine-animal-tests/
• 22 Khodavirdipour A, Keramat F, Hashemi SH, Alikhani MY. SARS-CoV-2; from vaccine development to drug discovery and prevention guidelines. AIMS Mol Sci 2020; 7 (03) 281
• 23 Nguyen TM, Zhang Y, Pandolfi PP. Virus against virus: a potential treatment for 2019-nCov (SARS-CoV-2) and other RNA viruses. Cell Res 2020; 30 (03) 189-190
• 24 New kind of CRISPR technology to target RNA, including RNA viruses like coronavirus. Accessed January 14, 2021 at: https://www.sciencedaily.com/releases/2020/03/200316141514.htm
• 25 Cockrell AS, Yount BL, Scobey T. et al. A mouse model for MERS coronavirus-induced acute respiratory distress syndrome. Nat Microbiol 2016; 2 (02) 16226
• 26 Kellner MJ, Koob JG, Gootenberg JS, Abudayyeh OO, Zhang F. SHERLOCK: nucleic acid detection with CRISPR nucleases. Nat Protoc 2019; 14 (10) 2986-3012
• 27 Martineau AR, Forouhi NG. Vitamin D for COVID-19: a case to answer?. Lancet Diabetes Endocrinol 2020; 8 (09) 735-736